ライフサイエンスコーパス: glycaemic

1 uppressed the fetal femoral vasoconstrictor, glycaemic and lactate acidaemic responses during hypoxia

2 Glycaemic and lipid factors may play a vasoconstrictive

3 uded changes in uric acid concentrations and glycaemic and lipid variables.

4 Here we analyse glycaemic and metabolic control, cardiovascular risk, me

5 l follow-up identified enduring and emerging glycaemic and metformin legacy treatment effects.

6 Differences between clusters in glycaemic and renal progression were investigated and co

7 There were no significant differences across glycaemic categories in median LDL cholesterol at baseli

8 he incidence of the primary endpoint in each glycaemic category, but a greater absolute reduction in

9 Rapid glycaemic change in patients with uncontrolled diabetes

10 xposure, or were switched to the alternative glycaemic condition, or to an intermediate glucose conce

11 d endothelial cells between hyper- and normo-glycaemic conditions on bioenergetic and functional para

12 on was the same when adjusted for centre and glycaemic control (0.55 [0.30-1.03], p = 0.06).

13 type 2 diabetes mellitus who had inadequate glycaemic control (glycosylated haemoglobin [HbA(1c)] 7.

14 es in blood pressure, total cholesterol, and glycaemic control (haemoglobin A1c) after 2 years.

15 .0-12.6], p=0.0004), mainly through improved glycaemic control (HbA1c <7.0% [53 mmol/mol] in 45 [75%]

16 They were eligible when they had suboptimum glycaemic control (HbA1c 7.1-11.0% [54-97 mmol/mol]) des

17 8 years) with type 2 diabetes and inadequate glycaemic control (HbA1c 8-12% [64-108 mmol/mol]) despit

18 Associations between glycaemic control (HbA1c), episodes of diabetic ketoacid

19 with diagnosed diabetes, (2) proportion with glycaemic control (measured HbA(1c) <7.0%), (3) proporti

20 or if overweight, metformin) or conventional glycaemic control (primarily diet).

21 a 3 month run-in to optimise risk factor and glycaemic control (single-blind placebo in the final mon

22 ndomly allocated to receive either intensive glycaemic control (sulfonylurea or insulin, or if overwe

23 Clinical risk factors and glycaemic control alone cannot predict the development o

24 diabetes overall and by different levels of glycaemic control and albuminuria.

25 n to reduce the risk of diabetes and improve glycaemic control and blood lipids in patients with diab

26 Poor glycaemic control and consequent increased HbA(1c) level

27 or factor that contributes to long-term poor glycaemic control and diabetic ketoacidosis in this age

28 Poor glycaemic control and impaired renal function substantia

29 The inferior glycaemic control and increased risk of hypoglycaemia wi

30 dies have characterised the relation between glycaemic control and infectious disease, which we discu

31 c modulator of hGPR40, demonstrates improved glycaemic control and low hypoglycaemic risk in diabetic

32 nced microvascular perfusion, contributes to glycaemic control and maintenance of vascular health, st

33 Disparities in glycaemic control and other areas of care may lead to hi

34 iabetes, there are improvements in long-term glycaemic control and psychological distress but not in

35 e and liraglutide have been shown to improve glycaemic control and reduce bodyweight in patients with

36 in delivery is a promising option to improve glycaemic control and reduce the risk of hypoglycaemia.

37 us insulin therapy has been shown to improve glycaemic control and reduce the risk of long-term compl

38 peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with typ

39 T-2 inhibitor therapy significantly improves glycaemic control and reduces bodyweight in patients wit

40 a glucagon-like peptide-1 analogue, improves glycaemic control and reduces bodyweight in patients wit

41 ith type 1 diabetes increased with worsening glycaemic control and renal complications.

42 fects on cardiovascular risk factors such as glycaemic control and reverse cholesterol transport.

43 owever, many patients do not achieve optimum glycaemic control and therefore new therapies are necess

44 efficacy and tolerability, provided superior glycaemic control and weight loss compared with sitaglip

45 tter treatment approaches for achieving good glycaemic control are badly needed.

46 ment of depression as well as improvement in glycaemic control as a marker for subsequent diabetes ou

47 es mellitus and are associated with improved glycaemic control as well as with reductions in body mas

48 s with relapse, however, maintained adequate glycaemic control at 10 years (mean HbA(1c) 6.7% [SD 0.2

49 ion (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they ta

50 tide was the most effective GLP-1RA drug for glycaemic control by reducing haemoglobin A(1c) and fast

51 Strict glycaemic control can decrease development and progressi

52 y closed-loop insulin delivery would improve glycaemic control compared with conventional subcutaneou

53 tor agonist treatment, resulting in improved glycaemic control compared with its components given alo

54 om health-care professionals offers superior glycaemic control compared with support from health-care

55 of vascular risk factors and optimisation of glycaemic control could have therapeutic benefit.

56 ients with type 2 diabetes mellitus and poor glycaemic control despite insulin therapy, with or witho

57 Patients with type 2 diabetes who had poor glycaemic control despite multiple daily injections with

58 Mean HbA1c was used to assess glycaemic control during follow-up.

59 reatment of type 2 diabetes have been led by glycaemic control for decades.

60 Intensive glycaemic control had no significant effect on events of

61 At 6 months, glycaemic control had worsened in the control group (mea

62 Intensive insulin therapy with tight glycaemic control has been advocated for improving outco

63 ct to insulin therapy in IDDM, might improve glycaemic control in adolescents; we investigated the ef

64 a do not support use of metformin to improve glycaemic control in adults with long-standing type 1 di

65 that severe periodontitis adversely affects glycaemic control in diabetes and glycaemia in non-diabe

66 diagnostic assays for the long-term mark of glycaemic control in diabetes.

67 chological problems are associated with poor glycaemic control in diabetes.

68 Intensive treatment to achieve good glycaemic control in diabetic patients is limited by a h

69 s suggest setting individualised targets for glycaemic control in elderly patients with type 2 diabet

70 lts of randomised controlled trials of tight glycaemic control in hospital inpatients might vary with

71 Good glycaemic control in insulin-dependent diabetes mellitus

72 und, has been shown to significantly improve glycaemic control in large-scale clinical trials, and sh

73 de could be considered for the management of glycaemic control in middle-aged and older people with t

74 Poorer glycaemic control in participants with known diabetes wa

75 is an effective treatment option to improve glycaemic control in patients receiving nutritional supp

76 gest that sacubitril/valsartan might enhance glycaemic control in patients with diabetes and HFrEF.

77 sing adjunct treatment to insulin to improve glycaemic control in patients with inadequately controll

78 Whether these actions contribute to improved glycaemic control in patients with insulin resistance wa

79 view aims to appraise the evidence for tight glycaemic control in patients with neurological injury.

80 d the effect of dapagliflozin-saxagliptin on glycaemic control in patients with type 2 diabetes and m

81 Optimum glycaemic control in patients with type 2 diabetes is im

82 TERPRETATION: TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with

83 -like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes.

84 educe hepatic fat content (HFC) and increase glycaemic control in pre-diabetic patients with non-alco

85 europathy caused by an abrupt improvement in glycaemic control in the setting of chronic hyperglycaem

86 The evidence for improved glycaemic control in the treatment of depression by use

87 Effective glycaemic control in type 1 diabetes mellitus usually re

88 s to assess their effectiveness in improving glycaemic control in type 2 diabetes.

89 rent clinical use in improving post-prandial glycaemic control in type 2 diabetics.

90 Comprehensive glycaemic control information should account for more th

91 nt intensification leading to sustained good glycaemic control is essential to delay diabetic complic

92 n this age group, and evidence suggests that glycaemic control is often neglected.

93 However, continued monitoring of glycaemic control is warranted because of potential rela

94 Tight glycaemic control may result in hypoglycaemia, which in

95 The main outcome was long-term glycaemic control measured by percentage of glycated hae

96 INTERPRETATION: Our findings show that glycaemic control measured by time in the glucose range

97 Durability of glycaemic control might reduce disease burden and improv

98 Evidence suggests that better glycaemic control might reduce infection risk, but furth

99 se prandial insulin intensification provides glycaemic control non-inferior to a full basal-bolus reg

100 The deterioration in glycaemic control observed in patients aged 10-20 years

101 tic subtype defines treatment, with improved glycaemic control on sulfonylurea treatment for most pat

102 No therapy altered glycaemic control or body weight.

103 Tight glycaemic control reduces microvascular complications in

104 or the treatment of type 2 diabetes, optimum glycaemic control remains challenging for many patients

105 Intensive glycaemic control resulted in a 17% reduction in events

106 Although diabetes and poor glycaemic control significantly increase the risk of tub

107 Overall, intensive compared with standard glycaemic control significantly reduces coronary events

108 Target-based intensive glycaemic control strategies (RR 1.00, 95% CI 0.88-1.13;

109 ess of a continuous, day-and-night automated glycaemic control system using insulin and glucagon has

110 were randomly assigned to receive intensive glycaemic control targeting HbA(1c) to less than 6.0% (4

111 There is more uncertainty about appropriate glycaemic control targets in this age group, and evidenc

112 ovided significantly greater improvements in glycaemic control than did exenatide twice a day, and wa

113 ed in a significantly greater improvement in glycaemic control than did glargine and represents a new

114 essation is associated with deterioration in glycaemic control that lasts for 3 years and is unrelate

115 lbumin are markers of short-term (2-4 weeks) glycaemic control that might add complementary prognosti

116 l prescription of blood pressure, lipid, and glycaemic control treatments for adults with type 2 diab

117 Worse glycaemic control was associated with increased risk of

118 uration of diabetes in late midlife and poor glycaemic control were associated with accelerated cogni

119 rmin (>/=1500 mg per day) and had inadequate glycaemic control were randomly assigned to receive one

120 l tests, vibration perception-threshold, and glycaemic control were unchanged.

121 rofile of longer than 42 h, provided similar glycaemic control when injected three times a week (IDeg

122 ance of monitoring fetal growth and maternal glycaemic control when treating GDM.

123 ype 1 diabetes because it provides effective glycaemic control while lowering the risk of nocturnal h

124 preparations has the potential for improving glycaemic control with a high degree of patient acceptan

125 th type 2 diabetes who do not achieve target glycaemic control with conventional insulin treatment, a

126 ts with type 2 diabetes who had insufficient glycaemic control with diet and exercise alone.

127 e 2 diabetes in patients who have inadequate glycaemic control with metformin alone.

128 type 2 diabetes who did not achieve adequate glycaemic control with metformin alone.

129 ged 18 years and older, who had insufficient glycaemic control with metformin either alone or in comb

130 n for patients who do not achieve sufficient glycaemic control with metformin therapy.

131 apagliflozin in patients who have inadequate glycaemic control with metformin.

132 ients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.

133 ncentrations to less than 8 mmol/L (moderate glycaemic control), while avoiding mild hypoglycaemia (<

134 prior glycaemic exposure despite subsequent glycaemic control, a phenomenon called metabolic memory.

135 es, including fear of hypoglycaemia, loss of glycaemic control, and inadequate knowledge around exerc

136 ther owners experience facilitated tightened glycaemic control, and wider psychosocial benefits.

137 uction (plasma lipid levels, blood pressure, glycaemic control, body weight and non-smoking status).

138 otential value of alert dogs, for increasing glycaemic control, client independence and consequent qu

139 t, adverse effects of periodontal disease on glycaemic control, diabetes complications, and developme

140 Our findings suggest that disparity in glycaemic control, diabetes-related monitoring, and pres

141 n treatment is thought to contribute to poor glycaemic control, diabetic ketoacidosis, and brittle di

142 characterized by excess adiposity, impaired glycaemic control, dyslipidaemia and moderate hypertensi

143 rary data as to whether disparities exist in glycaemic control, monitoring, and prescribing in people

144 address high unmet medical need via improved glycaemic control, several clinical trials have been don

145 enhanced prevention measures preoperatively (glycaemic control, skin decontamination, decolonisation,

146 rticipants, their age, duration of diabetes, glycaemic control, type of psychological therapy, its mo

147 Maternal outcome measures were glycaemic control, weight gain, and treatment failure.

148 Good glycaemic control, which reduces long-term diabetes comp

149 once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with li

150 once weekly exenatide led to improvements in glycaemic control, with greater reductions noted with li

151 ion within 8 weeks of a large improvement in glycaemic control-specified as a decrease in glycosylate

152 and we consider alternatives for monitoring glycaemic control.

153 ride-exposed groups, independent of maternal glycaemic control.

154 lyses show small to moderate improvements in glycaemic control.

155 -cell mass and insulin content, and improves glycaemic control.

156 they are unlikely to be related to improved glycaemic control.

157 es is dependent on both disease duration and glycaemic control.

158 CD diagnosis does not impact on T1DM glycaemic control.

159 most effective treatment for weight loss and glycaemic control.

160 ere is little evidence that it may influence glycaemic control.

161 etary means for type 2 diabetics to exercise glycaemic control.

162 HbA(1c) of <7% and 37% had very poor (>/=9%) glycaemic control.

163 o glucose monitoring is required for tighter glycaemic control.

164 ntervention soon after diagnosis can improve glycaemic control.

165 nd brain volume of intensive versus standard glycaemic control.

166 tment, with comparatively little effect from glycaemic control.

167 pies improves person-centred outcomes beyond glycaemic control.

168 ving metabolic health, weight management and glycaemic control.

169 y be used as a bioactive food ingredient for glycaemic control.

170 s cardiovascular disease and a wide range of glycaemic control.

171 uctions in cardiovascular risk achieved with glycaemic control.

172 ting persistent vascular dysfunction despite glycaemic control.

173 increased with renal complications and poor glycaemic control.

174 t-transplant diabetes; establish the role of glycaemic control; and assess the role of new diabetic t

175 ellitus (GDM) is directly linked to maternal glycaemic control; however, this relationship may be alt

176 se of the high levels of glycaemia and rapid glycaemic deterioration noted in this population.

177 Prediabetes is a state of glycaemic dysregulation below the diagnostic threshold o

178 in advance of the development of obesity or glycaemic dysregulation.

179 xposure to HFD well in advance of obesity or glycaemic dysregulation.

180 We aimed to compare blood pressure and glycaemic effects of the SGLT2 inhibitor dapagliflozin w

181 not yet available to establish for how long glycaemic efficacy could be sustained during long-term t

182 Glycaemic efficacy of Technosphere inhaled insulin is lo

183 etes are limited and have demonstrated lower glycaemic efficacy than those for adult-onset type 2 dia

184 ability can represent the presence of excess glycaemic excursions and, consequently, the risk of hype

185 In patients with type 1 or type 2 diabetes, glycaemic exposure assessed as HbA1c correlates strongly

186 elated genes and phenotypes induced by prior glycaemic exposure despite subsequent glycaemic control,

187 5-year risk of glycaemic failure was lower in model-concordant versus m

188 tment decisions for achieving individualised glycaemic goals with minimal risk in this important popu

189 insulin, most patients do not meet clinical glycaemic goals, and diabetes remains an important medic

190 d profile, body composition, and fitness and glycaemic goals.

191 immune signalling, microbial translocation, glycaemic health and blood transcriptome in the wild-bor

192 o indicate potential for improvements in non-glycaemic health outcomes from CGM use.

193 lopment of dietary strategies to improve the glycaemic impact of starch-rich meals which could be tes

194 arbohydrate digestion to make foods of lower glycaemic impact.

195 Lowest glycaemic index (54.58) and the highest sensory scores (

196 ture, in vitro starch digestibility, in vivo glycaemic index (GI) and sensorial properties of biscuit

197 rial (RCT), of a lifestyle intervention (low glycaemic index (GI) diet plus physical activity) in pre

198 Clinical studies suggest a role for dietary glycaemic index (GI) in bodyweight regulation and diabet

199 This study addressed determinations of the glycaemic index (GI), antioxidant capacity (AC), and phe

200 enhanced nutritional characteristics and low glycaemic index (GI).

201 s employed to assess the effect on simulated glycaemic index (GI).

202 Carbohydrates with high glycaemic index are proposed to promote the development

203 Dietary carbohydrates with a high glycaemic index cause a high postprandial glucose and in

204 as an alternative in the elaboration of low glycaemic index foods.

205 MBB, WBB, OSB and MSB had a glycaemic index of 75+/-4, 71+/-5, 68+/-5 and 65+/-4, re

206 This study examined whether the glycaemic index of dietary carbohydrates is a determinan

207 PS) in reducing the starch digestibility and glycaemic index of noodles was investigated.

208 serum HDL-cholesterol concentration and the glycaemic index of the diet for both men (regression coe

209 Thus, the glycaemic index of the diet is a stronger predictor than

210 s-sectional study of middle-aged adults, the glycaemic index of the diet was the only dietary variabl

211 The estimated glycaemic index was higher in breads with higher hydrati

212 activity and reduced phytic acid content and glycaemic index, although a slight decrease in in vitro

213 ics, including the type of carbohydrate, the glycaemic index, and fat intake.

214 dietary patterns such as Mediterranean, low glycaemic index, moderately low carbohydrate, and vegeta

215 eads demonstrated better texture and reduced glycaemic index.

216 l ingredient in various foods to possess low-glycaemic index.

217 urdough fermentation with a presumable lower glycaemic index.

218 cated by impaired hypoglycaemia awareness or glycaemic lability, or who already receive immunosuppres

219 gnitude of the femoral vasoconstriction, the glycaemic, lactacidaemic and acidaemic responses and the

220 ated with the level of glycated haemoglobin, glycaemic level, and time of disease onset.

221 21 and 56) to determine the level of GI and glycaemic load (GL).

222 ntervention group, including reduced dietary glycaemic load, gestational weight gain, and maternal su

223 Compared with standard care, glycaemic lowering by various drugs or strategies might

224 efficacy of continuous, multiday, automated glycaemic management has not been tested in outpatient s

225 he long-term benefits and risks of automated glycaemic management with a bihormonal bionic pancreas.

226 generation of biofunctional ingredients for glycaemic management.

227 hat can be prevented or delayed by intensive glycaemic management.

228 Haemoglobin A1c (HbA1c) is a significant glycaemic marker for diabetes mellitus.

229 exenatide and dapagliflozin improved various glycaemic measures and cardiovascular risk factors in pa

230 status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes.

231 e converted systematically between different glycaemic metrics.

232 promote physiological adaptations, including glycaemic mobilization and corticosterone release.

233 icians dealing with patients with suboptimal glycaemic outcomes should be aware of these potential is

234 We aimed to assess glycaemic outcomes when switching from multiple daily in

235 -0.846), and after additional adjustment for glycaemic parameters (model-2, OR: 0.670, 95%CI: 0.511-0

236 for T2DM must show meaningful reductions in glycaemic parameters as well as cardiovascular safety.

237 r of the MALT1 gene, involved in insulin and glycaemic pathways, and related to taurocholate levels i

238 nnel abnormality can result in a fluctuating glycaemic phenotype.

239 uous clinical features (age at diagnosis for glycaemic progression and baseline renal function for re

240 Clusters showed differences in glycaemic progression, but a model using age at diagnosi

241 auses of monogenic diabetes helps understand glycaemic regulation in humans.

242 Novel approaches to glycaemic regulation include use of inhibitors of the so

243 ng sequentially numbered sealed envelopes to glycaemic regulation with a bihormonal bionic pancreas o

244 icipant weight, was able to achieve superior glycaemic regulation without the need for carbohydrate c

245 icipant weight, was able to achieve superior glycaemic regulation without the need for carbohydrate c

246 ways, including altered absorption kinetics, glycaemic response and the gut microbiota composition an

247 A similar trend was observed for glycaemic response in vivo.

248 ns could be an innovative route to alter the glycaemic response of carbohydrate-rich foods.

249 monstrate that patients vary widely in their glycaemic response to critical illness and response to i

250 Glycaemic response to metformin is heritable, thus glyca

251 mic response to metformin is heritable, thus glycaemic response to metformin is, in part, intrinsic t

252 We aimed to establish the heritability of glycaemic response to metformin using the genome-wide co

253 The heritability of glycaemic response to metformin varied by response pheno

254 whom 2085 had enough clinical data to define glycaemic response to metformin.

255 stimate heritability for four definitions of glycaemic response to metformin: absolute reduction in H

256 We aimed to see whether the glycaemic response to the sulphonylurea gliclazide and t

257 sed in the treatment of type 2 diabetes, but glycaemic response to this drug is highly variable.

258 Clusters differed in glycaemic response, with a particular benefit for thiazo

259 antagonistic or synergic effect on predicted glycaemic response.

260 and steamed bread was healthier in terms of glycaemic response.

261 d to an antagonistic effect on the predicted glycaemic response.

262 ration conditions, is a major determinant of glycaemic response.

263 y diminished the femoral vasoconstrictor and glycaemic responses to hypoxaemia, and attenuated the in

264 Combining glycaemic results with clinical information improves pro

265 ct of alirocumab on cardiovascular events by glycaemic status at baseline (diabetes, prediabetes, or

266 51.1 years [SD 12.7]) with available data on glycaemic status from at least one follow-up visit were

267 sed to quantify the effect of previous (DPP) glycaemic status on risk of later (DPPOS) diabetes and n

268 fects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on gl

269 patients of acromegaly irrespective of their glycaemic status.

270 insoluble fibre, essential amino acids, low glycaemic sugars, resistant to thermal food processing a

271 Individualised glycaemic target levels are achievable with vildagliptin

272 of life that are independent of a particular glycaemic target.

273 es and anti-hyperglycaemic therapies emerge, glycaemic targets will continue to evolve.

274 atment option for patients unable to achieve glycaemic targets with conventional insulin treatment.

275 ight management is as important as attaining glycaemic targets.

276 The AUC for the three underlying glycaemic tests was 65.0% (95% CI 63.0-66.9) for HbA(1c)

277 ) [HbA(1c)] of <6.0%) or standard (7.0-7.9%) glycaemic therapy.

278 tion of remission should include unambiguous glycaemic thresholds and emphasise duration.

279 and categorised by glucose-lowering therapy, glycaemic thresholds, and duration.

280 and 232 (87%) definitions specified numeric glycaemic thresholds.

281 cases, 76 344 non-cases; five studies), and glycaemic traits (concentrations of fasting glucose, 2-h

282 ce for an association between depression and glycaemic traits (eg, glucose, insulin, insulin sensitiv

283 otyped studies of CAD, MI, diabetes, lipids, glycaemic traits and adiposity to obtain unconfounded es

284 which have been previously linked to fasting glycaemic traits and insulin resistance in genome wide a

285 ney function, adiposity, metabolic syndrome, glycaemic traits or blood lipid concentrations).

286 Glycaemic traits such as fasting and post-challenge gluc

287 endelian randomisation-derived estimates for glycaemic traits were not significant (p>0.25).

288 etes, adiposity, blood pressure, lipids, and glycaemic traits), using two-sample Mendelian randomizat

289 D concentration with type 2 diabetes and the glycaemic traits, and compared them with that from a met

290 recent advances in the genetic aetiology of glycaemic traits, and the resulting biological insights.

291 to the discovery of over 97 loci influencing glycaemic traits.

292 blood-based metabolic traits, in addition to glycaemic values, could optimise estimation of diabetes

293 00 h) glycaemia (incremental AUC [iAUC]) and glycaemic variability (%coefficient of variation [%CV])

294 t evidence examining the association between glycaemic variability and diabetes-related complications

295 flexibility, and a somewhat higher degree of glycaemic variability and hypoglycaemia when compared to

296 dent risk factor for diabetes complications, glycaemic variability can represent the presence of exce

297 Glycaemic variability is an integral component of glucos

298 Glycaemic variability is currently defined by a large an

299 ay and between-day variability) or long-term glycaemic variability, which is usually based on serial

300 h-risk state for diabetes that is defined by glycaemic variables that are higher than normal, but low